Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 752 results for "amgen rank"

Amgen Inc. Bonds: A Rare Combination Of Low Risk And High Value
Seeking Alpha

Amgen Inc. Bonds: A Rare Combination Of Low Risk And High Value

Summary Amgen default probabilities rank in the best 1% of 445 pharmaceutical and health care firms at all maturities. Amgen bonds also offer a very strong ratio of credit spread to default probabilities at all maturities. Among heavily traded ... Seeking Alpha, 1 month ago
Amgen (AMGN) Showing Resistance Near $139.38 Individual.com, 1 day ago
[x]  

2 images for "amgen rank"

Scottrade, 1 week ago
Rediff.com, 1 month ago

Amgen Upgraded to Strong Buy

On Aug 21, Zacks Investment Research upgraded Amgen Inc. ( AMGN ) to a Zacks Rank #1 (Strong Buy). Why the Upgrade? Amgen came out with strong second quarter results and an improved outlook for 2014 on Jul 29. The biotech company's earnings ...
 Yahoo! Finance6 days ago Amgen Upgraded to Strong Buy - Analyst Blog  Zacks.com6 days ago

Shares of Amgen Rank the Lowest in Terms of Projected Earnings Growth in the Biotechnology Industry (AMGN, SCLN, REGN, CELG, PDLI)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future ...
 Individual.com1 week ago Shares of Halozyme Therapeutics Rank the Lowest in Terms of Sales Growth in the Biotechnology Industry (HALO, SPPI, GHDX, AMGN, ACOR)  Comtex SmarTrend4 weeks ago Top 5 Companies in the Biotechnology Industry With the Lowest P/E Ratio (AFFY, ENZN, PDLI, MYGN, AMGN)  Comtex SmarTrend1 week ago Alkermes has the Lowest Future Earnings Growth in the Biotechnology Industry (ALKS, PDLI, AMGN, ALXN, ACOR)  Comtex SmarTrend4 weeks ago

Amgen's Chronic Heart Failure Drug Gets Priority Review

Amgen Inc. ( AMGN ) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (:NDA) for its pipeline candidate, ivabradine. Amgen is looking to get ivabradine approved for the treatment ...
 Yahoo! Finance4 hours ago

Potential Amgen (AMGN) Trade Has 1.43% Downside Protection

With bullish technical indicators and a 4 STARS (out of 5) buy ranking from Standard & PooraEUR(TM)s, Amgen Inc (http://www.marketintelligencecenter.com/symbol/AMGN"AMGN) could be an attractive play for investors according to ...
 Individual.com2 days ago Potential Amgen (AMGN) Trade Has 2.55% Downside Protection  TradingCharts.com2 weeks ago Potential Amgen (AMGN) Trade Has 0.88% Downside Protection  Individual.com1 month ago Potential Amgen (AMGN) Trade Targets 4.52% Return  TradingCharts.com1 month ago
[x]  
Scottrade

The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen

For Immediate Release Chicago, IL August 21, 2014 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
 Yahoo! Finance1 week ago THE ZACKS ANALYST BLOG HIGHLIGHTS : Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen  4 Traders1 week ago Take Two Interactive, Loews, Amgen, Vertex and Regeneron highlighted as Zacks Bull and Bear of the D …  Yahoo! Finance3 weeks ago The Zacks Analyst Blog Highlights:Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen  Wall Street Select1 month ago
[x]  

Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416

Amgen Inc. ( AMGN ) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study evaluating the candidate for the treatment of secondary hyperparathyroidism in patients with chronic kidney ...
 Yahoo! Finance1 week ago

Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails

Amgen ( AMGN ) suffered a major setback when its phase III study, FOCUS (Car F ilz O mib for Advan C ed Refractory M U ltiple Myeloma European S tudy) on multiple myeloma treatment, Kyprolis did not meet its primary endpoint. The open-label study ...
 Yahoo! Finance2 weeks ago Amgen's Multiple Myeloma Drug Kyprolis Succeeds  Yahoo! Finance3 weeks ago
[x]  

Q3 Guidance And Beyond Holds The Key

Elsewhere this morning, Amgen (AMZN) reported positive late-stage data on Kyprolis, a treatment for relapsed multiple myeloma. Shares of this Zacks Rank #3 company are up 3.5% in
 Yahoo! Finance3 weeks ago

Amgen Beats on Q2 Earnings & Revs, Ups View & Plans Job Cuts

Amgen ( AMGN ) reported second quarter 2014 earnings of $2.37 per share, well above the Zacks Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating ...
 Yahoo! Finance4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less